Immix Biopharma, Inc. IMMX
10.97
(0.73)
(6.24%)
as of 25 Sep
- Market cap
- $844.3M
- P/E
- 0.0×
Follow IMMX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.20 | 0.10 | 90.03 | 11.70 | 5.32 | 2.33 | 10.01 |
Net Debt/EBITDA |
— | 0.87 | (8.10) | 13.66 | 1.64 | 1.09 | 0.78 | 3.39 |
Debt/Assets |
0.00% | 0.00% | 750.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | (0.86) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.81 | 0.35 | 0.07 | 0.90 | 0.74 | 0.68 | 0.81 |
Capex/Depreciation |
— | (6.64) | 0.00 | (0.01) | 0.00 | (9.47) | (10.21) | (2.01) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 27.41% | (367.80%) | (52.84%) | (105.07%) | (146.76%) | (55.00%) | |
| — | (206.34%) | (154.86%) | (260.35%) | (49.73%) | (88.57%) | (100.82%) | (46.07%) | |
ROIC |
— | 0.00% | 0.00% | (244.50%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 26.68% | 24.27% | (135.54%) | (60.39%) | (95.72%) | (163.11%) | (31.44%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.24) | (0.12) | (0.43) | (0.53) | (0.66) | (0.56) | (0.75) |
Cash per Share |
— | 0.22 | 0.12 | 4.80 | 0.97 | 1.01 | 0.63 | 3.05 |
Shareholders Equity per Share |
— | (1.08) | (1.40) | 4.90 | 0.95 | 0.93 | 0.47 | 2.85 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (1.08) | (1.40) | 4.90 | 0.95 | 0.93 | 0.47 | 2.85 |
Free Cash Flow |
— | (0.80) | (0.40) | (1.59) | (7.41) | (11.42) | (15.77) | (24.66) |
Working Capital |
— | (3.66) | (4.74) | 17.98 | 13.62 | 16.07 | 11.51 | 91.13 |
Capital Expenditures |
— | (0.01) | — | 0.00 | — | (0.05) | (1.18) | (0.73) |
Net Current Asset Value |
— | (3.66) | (4.74) | 17.98 | 13.15 | 16.07 | 10.50 | 90.19 |
| Other line items | ||||||||
Quick Ratio |
— | 0.20 | 0.10 | 87.48 | 10.75 | 5.02 | 2.26 | 9.93 |
Depreciation/Fixed assets |
— | 0.11 | 0.31 | 10.63 | 0.58 | 0.11 | 0.07 | 0.14 |
Cash ROIC |
— | 27.46% | 142.35% | (4.48%) | (27.87%) | (33.88%) | (52.81%) | (13.62%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.23) | (0.12) | (0.43) | (0.53) | (0.66) | (0.52) | (0.73) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | (0.02) |
Average Receivables |
— | — | 0.15 | 0.08 | 0.14 | 0.71 | 1.57 | — |
Average Payables |
— | — | 0.25 | 0.20 | 0.71 | 2.50 | 6.17 | 9.30 |
Average Assets |
— | 0.47 | 0.74 | 9.37 | 16.55 | 17.42 | 21.44 | 63.89 |
Average Common Equity |
— | — | (4.19) | 6.63 | 15.57 | 14.68 | 14.73 | 53.52 |
Capex to Sales |
— | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates